KRAS
KRAS (KRas proto-oncogene, GTPase, also known as K-Ras4B, KRAS1 and KRAS2) is a small GTPase of the Ras family that acts as a signal transducer in the Ras-MAPK pathway. It binds GDP and GTP, has intrinsic GTPase activity and regulates cell proliferation and survival. Browse Assay Genie's current range of KRAS research reagents below, or read on for the biology behind the target.
KRAS is a signal transducer in the Ras-MAPK signalling pathway, which regulates cell proliferation and survival. Like other Ras proteins, it binds GDP and GTP and possesses intrinsic GTPase activity (EC 3.6.5.2). It activates MAPK1 and MAPK3, which results in phosphorylation and ultimately degradation of GJA1. In colorectal cancer cells, KRAS has also been described as promoting oncogenic events by inducing transcriptional silencing of tumour suppressor genes in a ZNF304-dependent manner.
The KRAS protein belongs to the small GTPase superfamily and the Ras family, and HGNC places the gene in the RAS type GTPase family. UniProt records its locations as the cell membrane, the endomembrane system and the cytoplasm. Its levels are also subject to control by ubiquitination: KRAS is recognised by LZTR1, which mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. According to the NCBI Gene summary, alternative splicing of the KRAS gene produces two isoforms that differ in the C-terminal region. Mouse and rat both carry an ortholog named Kras.
The gene takes its name from the Kirsten rat sarcoma viral oncogene, and earlier names include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog and KRAS proto-oncogene, GTPase. A single amino acid substitution is enough to produce an activating mutation. The resulting transforming protein is implicated in several malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. This makes KRAS a central subject in studies of Ras signalling and oncogenesis.
KRAS transduces signals through the Ras-MAPK pathway, activating MAPK1 and MAPK3 to regulate cell proliferation and survival.
A single amino acid substitution activates KRAS, and the transforming protein is implicated in lung, pancreatic and colorectal malignancies.
KRAS promotes transcriptional silencing of tumour suppressor genes in colorectal cancer cells in a ZNF304-dependent manner.
KRAS is recognised by LZTR1, which mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.
KRAS is a small GTPase that acts as a signal transducer in the Ras-MAPK pathway, regulating cell proliferation and survival. It binds GDP and GTP, has intrinsic GTPase activity and activates MAPK1 and MAPK3, which leads to phosphorylation and degradation of GJA1.
KRAS is also called K-Ras4B, KRAS1 and KRAS2, and its UniProt name is GTPase KRas. Older names include Kirsten rat sarcoma viral oncogene homolog. Alternative splicing gives two isoforms that differ in the C-terminal region.
An activating single amino acid substitution makes KRAS a transforming protein implicated in lung adenocarcinoma, mucinous adenoma, pancreatic ductal carcinoma and colorectal carcinoma. Mouse and rat orthologs are both named Kras; check the datasheet of any product for its validated reactivity.
Ras-MAPK pathway components, ubiquitination regulators and colorectal cancer-related proteins connected to KRAS.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P01116; product specifications from Assay Genie datasheets.